Valmet's Q2 Net Sales and Comparable EBITA Increased
Valmet Oyj released its half-year financial review on July 24, 2026. The company reported a six percent increase in net sales and a six percent rise in comparable EBITA for the second quarter.
Valmet Reports Increased Second Quarter Net Sales and Profit
Espoo, Finland – July 24, 2026 – Valmet Oyj announced today that its net sales grew by six percent to EUR 1,315 million in April-June 2026, up from EUR 1,241 million in the corresponding period last year. Concurrently, the company's comparable EBITA (earnings before interest, taxes, and amortization) rose by six percent to EUR 152 million, aligning with its earlier forecast for growth towards the end of the year.
The company's orders received amounted to EUR 1,373 million, a decrease of 10 percent compared to the previous year. This decline was primarily driven by lower capital project order intake within the Biomaterial Solutions and Services segment. However, Valmet reaffirmed its guidance for the full year 2026, estimating that net sales will remain at the previous year's level and comparable EBITA will either stay flat or increase.
Earnings per share (EPS) for Valmet shareholders increased to EUR 0.40 (EUR 0.15) in the second quarter. This rise is largely attributed to the financial comparison period of the previous year, which included one-time restructuring expenses related to the operating model renewal. For the January-June period, EPS stood at EUR 0.59 (EUR 0.48).
Valmet's short-term market outlook for July-December 2026 suggests that the market for Process Performance Solutions will experience low year-over-year growth. The market conditions for Biomaterial Solutions and Services are expected to remain similar to the second quarter. Persistent geopolitical and global economic uncertainty continues to limit short-term market visibility.